nodes	percent_of_prediction	percent_of_DWPC	metapath
Trifluoperazine—EBPL—Tamoxifen—pancreatic cancer	0.349	0.493	CbGbCtD
Trifluoperazine—EBP—Tamoxifen—pancreatic cancer	0.115	0.163	CbGbCtD
Trifluoperazine—UGT1A4—Tamoxifen—pancreatic cancer	0.105	0.148	CbGbCtD
Trifluoperazine—Promazine—Tamoxifen—pancreatic cancer	0.0966	1	CrCrCtD
Trifluoperazine—SIGMAR1—Tamoxifen—pancreatic cancer	0.0495	0.0698	CbGbCtD
Trifluoperazine—XDH—Doxorubicin—pancreatic cancer	0.0252	0.0356	CbGbCtD
Trifluoperazine—CYP1A2—Dacarbazine—pancreatic cancer	0.00985	0.0139	CbGbCtD
Trifluoperazine—CYP1A2—Tamoxifen—pancreatic cancer	0.00784	0.0111	CbGbCtD
Trifluoperazine—ABCB1—Tamoxifen—pancreatic cancer	0.00685	0.00968	CbGbCtD
Trifluoperazine—CYP1A2—Erlotinib—pancreatic cancer	0.00666	0.00941	CbGbCtD
Trifluoperazine—ABCB1—Gemcitabine—pancreatic cancer	0.0059	0.00834	CbGbCtD
Trifluoperazine—ABCB1—Erlotinib—pancreatic cancer	0.00583	0.00823	CbGbCtD
Trifluoperazine—CYP1A2—Fluorouracil—pancreatic cancer	0.00578	0.00816	CbGbCtD
Trifluoperazine—ABCB1—Irinotecan—pancreatic cancer	0.00526	0.00743	CbGbCtD
Trifluoperazine—ABCB1—Docetaxel—pancreatic cancer	0.00386	0.00545	CbGbCtD
Trifluoperazine—ABCB1—Sunitinib—pancreatic cancer	0.00384	0.00542	CbGbCtD
Trifluoperazine—HTR2A—enteric nervous system—pancreatic cancer	0.00374	0.187	CbGeAlD
Trifluoperazine—ABCB1—Doxorubicin—pancreatic cancer	0.00288	0.00406	CbGbCtD
Trifluoperazine—CALY—islet of Langerhans—pancreatic cancer	0.00237	0.119	CbGeAlD
Trifluoperazine—S100A4—islet of Langerhans—pancreatic cancer	0.00205	0.102	CbGeAlD
Trifluoperazine—S100A4—pancreas—pancreatic cancer	0.00144	0.0719	CbGeAlD
Trifluoperazine—S100A4—digestive system—pancreatic cancer	0.00123	0.0614	CbGeAlD
Trifluoperazine—UGT1A4—digestive system—pancreatic cancer	0.00108	0.0539	CbGeAlD
Trifluoperazine—EBP—Azacitidine—Gemcitabine—pancreatic cancer	0.000931	1	CbGdCrCtD
Trifluoperazine—CALM2—gall bladder—pancreatic cancer	0.000899	0.0449	CbGeAlD
Trifluoperazine—XDH—digestive system—pancreatic cancer	0.000787	0.0394	CbGeAlD
Trifluoperazine—CALM3—islet of Langerhans—pancreatic cancer	0.00075	0.0375	CbGeAlD
Trifluoperazine—SIGMAR1—islet of Langerhans—pancreatic cancer	0.000671	0.0335	CbGeAlD
Trifluoperazine—CALM2—islet of Langerhans—pancreatic cancer	0.000589	0.0295	CbGeAlD
Trifluoperazine—CALM1—islet of Langerhans—pancreatic cancer	0.000586	0.0293	CbGeAlD
Trifluoperazine—CALM3—pancreas—pancreatic cancer	0.000527	0.0264	CbGeAlD
Trifluoperazine—SIGMAR1—pancreas—pancreatic cancer	0.000471	0.0236	CbGeAlD
Trifluoperazine—CALM2—pancreas—pancreatic cancer	0.000414	0.0207	CbGeAlD
Trifluoperazine—CALM1—pancreas—pancreatic cancer	0.000412	0.0206	CbGeAlD
Trifluoperazine—CALM2—digestive system—pancreatic cancer	0.000354	0.0177	CbGeAlD
Trifluoperazine—CALM1—digestive system—pancreatic cancer	0.000352	0.0176	CbGeAlD
Trifluoperazine—CYP1A2—digestive system—pancreatic cancer	0.000274	0.0137	CbGeAlD
Trifluoperazine—Agranulocytosis—Fluorouracil—pancreatic cancer	0.000262	0.00311	CcSEcCtD
Trifluoperazine—Dyskinesia—Epirubicin—pancreatic cancer	0.00026	0.00309	CcSEcCtD
Trifluoperazine—Amenorrhoea—Doxorubicin—pancreatic cancer	0.000257	0.00306	CcSEcCtD
Trifluoperazine—HRH1—digestive system—pancreatic cancer	0.000257	0.0128	CbGeAlD
Trifluoperazine—Skin disorder—Erlotinib—pancreatic cancer	0.000254	0.00302	CcSEcCtD
Trifluoperazine—Angioedema—Sunitinib—pancreatic cancer	0.000254	0.00302	CcSEcCtD
Trifluoperazine—Anorexia—Tamoxifen—pancreatic cancer	0.000252	0.003	CcSEcCtD
Trifluoperazine—Oedema peripheral—Gemcitabine—pancreatic cancer	0.000252	0.003	CcSEcCtD
Trifluoperazine—Gait disturbance—Epirubicin—pancreatic cancer	0.00025	0.00297	CcSEcCtD
Trifluoperazine—Anorexia—Erlotinib—pancreatic cancer	0.000249	0.00297	CcSEcCtD
Trifluoperazine—Leukopenia—Sunitinib—pancreatic cancer	0.000249	0.00296	CcSEcCtD
Trifluoperazine—Hepatocellular injury—Epirubicin—pancreatic cancer	0.000244	0.0029	CcSEcCtD
Trifluoperazine—Cough—Sunitinib—pancreatic cancer	0.000242	0.00288	CcSEcCtD
Trifluoperazine—Convulsion—Sunitinib—pancreatic cancer	0.000241	0.00286	CcSEcCtD
Trifluoperazine—Dyskinesia—Doxorubicin—pancreatic cancer	0.00024	0.00286	CcSEcCtD
Trifluoperazine—Insomnia—Tamoxifen—pancreatic cancer	0.000239	0.00285	CcSEcCtD
Trifluoperazine—Insomnia—Erlotinib—pancreatic cancer	0.000237	0.00282	CcSEcCtD
Trifluoperazine—Dyspnoea—Tamoxifen—pancreatic cancer	0.000236	0.00281	CcSEcCtD
Trifluoperazine—ABCB1—islet of Langerhans—pancreatic cancer	0.000234	0.0117	CbGeAlD
Trifluoperazine—Dyspnoea—Erlotinib—pancreatic cancer	0.000233	0.00278	CcSEcCtD
Trifluoperazine—Gait disturbance—Doxorubicin—pancreatic cancer	0.000231	0.00275	CcSEcCtD
Trifluoperazine—Dry mouth—Sunitinib—pancreatic cancer	0.000231	0.00275	CcSEcCtD
Trifluoperazine—Decreased appetite—Tamoxifen—pancreatic cancer	0.00023	0.00274	CcSEcCtD
Trifluoperazine—Aplastic anaemia—Epirubicin—pancreatic cancer	0.000229	0.00272	CcSEcCtD
Trifluoperazine—Fatigue—Tamoxifen—pancreatic cancer	0.000228	0.00271	CcSEcCtD
Trifluoperazine—Decreased appetite—Erlotinib—pancreatic cancer	0.000228	0.00271	CcSEcCtD
Trifluoperazine—Dysphagia—Docetaxel—pancreatic cancer	0.000227	0.0027	CcSEcCtD
Trifluoperazine—Constipation—Tamoxifen—pancreatic cancer	0.000226	0.00269	CcSEcCtD
Trifluoperazine—Hepatocellular injury—Doxorubicin—pancreatic cancer	0.000226	0.00269	CcSEcCtD
Trifluoperazine—Fatigue—Erlotinib—pancreatic cancer	0.000226	0.00268	CcSEcCtD
Trifluoperazine—Constipation—Erlotinib—pancreatic cancer	0.000224	0.00266	CcSEcCtD
Trifluoperazine—Bronchospasm—Docetaxel—pancreatic cancer	0.000223	0.00265	CcSEcCtD
Trifluoperazine—Erythema—Gemcitabine—pancreatic cancer	0.000223	0.00265	CcSEcCtD
Trifluoperazine—Skin disorder—Sunitinib—pancreatic cancer	0.00022	0.00262	CcSEcCtD
Trifluoperazine—Muscle spasms—Irinotecan—pancreatic cancer	0.00022	0.00262	CcSEcCtD
Trifluoperazine—Erythema—Fluorouracil—pancreatic cancer	0.000219	0.00261	CcSEcCtD
Trifluoperazine—Anorexia—Sunitinib—pancreatic cancer	0.000216	0.00257	CcSEcCtD
Trifluoperazine—Pancytopenia—Docetaxel—pancreatic cancer	0.000215	0.00256	CcSEcCtD
Trifluoperazine—HTR2A—digestive system—pancreatic cancer	0.000214	0.0107	CbGeAlD
Trifluoperazine—Aplastic anaemia—Doxorubicin—pancreatic cancer	0.000212	0.00252	CcSEcCtD
Trifluoperazine—Urticaria—Tamoxifen—pancreatic cancer	0.00021	0.0025	CcSEcCtD
Trifluoperazine—Body temperature increased—Erlotinib—pancreatic cancer	0.000207	0.00246	CcSEcCtD
Trifluoperazine—Weight increased—Docetaxel—pancreatic cancer	0.000206	0.00246	CcSEcCtD
Trifluoperazine—Vision blurred—Fluorouracil—pancreatic cancer	0.000206	0.00246	CcSEcCtD
Trifluoperazine—Insomnia—Sunitinib—pancreatic cancer	0.000205	0.00244	CcSEcCtD
Trifluoperazine—Leukopenia—Irinotecan—pancreatic cancer	0.000205	0.00244	CcSEcCtD
Trifluoperazine—Dyspnoea—Sunitinib—pancreatic cancer	0.000202	0.0024	CcSEcCtD
Trifluoperazine—Photosensitivity—Epirubicin—pancreatic cancer	0.000202	0.0024	CcSEcCtD
Trifluoperazine—Cough—Irinotecan—pancreatic cancer	0.0002	0.00237	CcSEcCtD
Trifluoperazine—Leukopenia—Gemcitabine—pancreatic cancer	0.000199	0.00237	CcSEcCtD
Trifluoperazine—Jaundice—Docetaxel—pancreatic cancer	0.000197	0.00235	CcSEcCtD
Trifluoperazine—Eczema—Epirubicin—pancreatic cancer	0.000197	0.00234	CcSEcCtD
Trifluoperazine—Decreased appetite—Sunitinib—pancreatic cancer	0.000197	0.00234	CcSEcCtD
Trifluoperazine—Leukopenia—Fluorouracil—pancreatic cancer	0.000196	0.00233	CcSEcCtD
Trifluoperazine—Fatigue—Sunitinib—pancreatic cancer	0.000195	0.00232	CcSEcCtD
Trifluoperazine—Hypersensitivity—Tamoxifen—pancreatic cancer	0.000195	0.00232	CcSEcCtD
Trifluoperazine—Cough—Gemcitabine—pancreatic cancer	0.000194	0.00231	CcSEcCtD
Trifluoperazine—Constipation—Sunitinib—pancreatic cancer	0.000194	0.00231	CcSEcCtD
Trifluoperazine—Asthenia—Tamoxifen—pancreatic cancer	0.00019	0.00226	CcSEcCtD
Trifluoperazine—Convulsion—Fluorouracil—pancreatic cancer	0.00019	0.00226	CcSEcCtD
Trifluoperazine—Agranulocytosis—Docetaxel—pancreatic cancer	0.000189	0.00225	CcSEcCtD
Trifluoperazine—Increased appetite—Epirubicin—pancreatic cancer	0.000188	0.00224	CcSEcCtD
Trifluoperazine—Asthenia—Erlotinib—pancreatic cancer	0.000188	0.00223	CcSEcCtD
Trifluoperazine—Dermatitis exfoliative—Epirubicin—pancreatic cancer	0.000188	0.00223	CcSEcCtD
Trifluoperazine—Pruritus—Tamoxifen—pancreatic cancer	0.000187	0.00223	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Irinotecan—pancreatic cancer	0.000187	0.00222	CcSEcCtD
Trifluoperazine—Photosensitivity—Doxorubicin—pancreatic cancer	0.000187	0.00222	CcSEcCtD
Trifluoperazine—Pruritus—Erlotinib—pancreatic cancer	0.000185	0.0022	CcSEcCtD
Trifluoperazine—Anaphylactoid reaction—Epirubicin—pancreatic cancer	0.000183	0.00218	CcSEcCtD
Trifluoperazine—Eczema—Doxorubicin—pancreatic cancer	0.000182	0.00217	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Gemcitabine—pancreatic cancer	0.000182	0.00216	CcSEcCtD
Trifluoperazine—Hypoglycaemia—Epirubicin—pancreatic cancer	0.000181	0.00216	CcSEcCtD
Trifluoperazine—Body temperature increased—Sunitinib—pancreatic cancer	0.000179	0.00213	CcSEcCtD
Trifluoperazine—Oedema peripheral—Docetaxel—pancreatic cancer	0.000179	0.00213	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Fluorouracil—pancreatic cancer	0.000179	0.00213	CcSEcCtD
Trifluoperazine—Anorexia—Irinotecan—pancreatic cancer	0.000178	0.00212	CcSEcCtD
Trifluoperazine—Skin disorder—Gemcitabine—pancreatic cancer	0.000177	0.0021	CcSEcCtD
Trifluoperazine—Dizziness—Tamoxifen—pancreatic cancer	0.000175	0.00208	CcSEcCtD
Trifluoperazine—Hypotension—Irinotecan—pancreatic cancer	0.000174	0.00207	CcSEcCtD
Trifluoperazine—Increased appetite—Doxorubicin—pancreatic cancer	0.000174	0.00207	CcSEcCtD
Trifluoperazine—Dermatitis exfoliative—Doxorubicin—pancreatic cancer	0.000174	0.00207	CcSEcCtD
Trifluoperazine—Anorexia—Gemcitabine—pancreatic cancer	0.000173	0.00206	CcSEcCtD
Trifluoperazine—Dizziness—Erlotinib—pancreatic cancer	0.000173	0.00206	CcSEcCtD
Trifluoperazine—Anorexia—Fluorouracil—pancreatic cancer	0.00017	0.00203	CcSEcCtD
Trifluoperazine—Hypotension—Gemcitabine—pancreatic cancer	0.00017	0.00202	CcSEcCtD
Trifluoperazine—Anaphylactoid reaction—Doxorubicin—pancreatic cancer	0.000169	0.00201	CcSEcCtD
Trifluoperazine—Insomnia—Irinotecan—pancreatic cancer	0.000169	0.00201	CcSEcCtD
Trifluoperazine—Cardiac arrest—Epirubicin—pancreatic cancer	0.000168	0.002	CcSEcCtD
Trifluoperazine—Hypoglycaemia—Doxorubicin—pancreatic cancer	0.000168	0.002	CcSEcCtD
Trifluoperazine—Hypotension—Fluorouracil—pancreatic cancer	0.000167	0.00199	CcSEcCtD
Trifluoperazine—Hypersensitivity—Sunitinib—pancreatic cancer	0.000167	0.00199	CcSEcCtD
Trifluoperazine—Rash—Tamoxifen—pancreatic cancer	0.000167	0.00198	CcSEcCtD
Trifluoperazine—Dermatitis—Tamoxifen—pancreatic cancer	0.000167	0.00198	CcSEcCtD
Trifluoperazine—Dyspnoea—Irinotecan—pancreatic cancer	0.000166	0.00198	CcSEcCtD
Trifluoperazine—Somnolence—Irinotecan—pancreatic cancer	0.000166	0.00197	CcSEcCtD
Trifluoperazine—Headache—Tamoxifen—pancreatic cancer	0.000166	0.00197	CcSEcCtD
Trifluoperazine—Rash—Erlotinib—pancreatic cancer	0.000165	0.00196	CcSEcCtD
Trifluoperazine—Dermatitis—Erlotinib—pancreatic cancer	0.000165	0.00196	CcSEcCtD
Trifluoperazine—ABCB1—pancreas—pancreatic cancer	0.000165	0.00823	CbGeAlD
Trifluoperazine—Insomnia—Gemcitabine—pancreatic cancer	0.000164	0.00196	CcSEcCtD
Trifluoperazine—Headache—Erlotinib—pancreatic cancer	0.000164	0.00195	CcSEcCtD
Trifluoperazine—Asthenia—Sunitinib—pancreatic cancer	0.000163	0.00193	CcSEcCtD
Trifluoperazine—Decreased appetite—Irinotecan—pancreatic cancer	0.000162	0.00193	CcSEcCtD
Trifluoperazine—Dyspnoea—Gemcitabine—pancreatic cancer	0.000162	0.00193	CcSEcCtD
Trifluoperazine—Insomnia—Fluorouracil—pancreatic cancer	0.000162	0.00192	CcSEcCtD
Trifluoperazine—Somnolence—Gemcitabine—pancreatic cancer	0.000162	0.00192	CcSEcCtD
Trifluoperazine—Fatigue—Irinotecan—pancreatic cancer	0.000161	0.00191	CcSEcCtD
Trifluoperazine—Pruritus—Sunitinib—pancreatic cancer	0.00016	0.00191	CcSEcCtD
Trifluoperazine—Constipation—Irinotecan—pancreatic cancer	0.00016	0.0019	CcSEcCtD
Trifluoperazine—Dyspnoea—Fluorouracil—pancreatic cancer	0.000159	0.0019	CcSEcCtD
Trifluoperazine—Somnolence—Fluorouracil—pancreatic cancer	0.000159	0.00189	CcSEcCtD
Trifluoperazine—Erythema—Docetaxel—pancreatic cancer	0.000158	0.00188	CcSEcCtD
Trifluoperazine—Decreased appetite—Gemcitabine—pancreatic cancer	0.000158	0.00188	CcSEcCtD
Trifluoperazine—Nausea—Tamoxifen—pancreatic cancer	0.000157	0.00187	CcSEcCtD
Trifluoperazine—Fatigue—Gemcitabine—pancreatic cancer	0.000157	0.00186	CcSEcCtD
Trifluoperazine—Muscular weakness—Epirubicin—pancreatic cancer	0.000156	0.00186	CcSEcCtD
Trifluoperazine—Cardiac arrest—Doxorubicin—pancreatic cancer	0.000156	0.00185	CcSEcCtD
Trifluoperazine—Constipation—Gemcitabine—pancreatic cancer	0.000155	0.00185	CcSEcCtD
Trifluoperazine—Nausea—Erlotinib—pancreatic cancer	0.000155	0.00185	CcSEcCtD
Trifluoperazine—Decreased appetite—Fluorouracil—pancreatic cancer	0.000155	0.00185	CcSEcCtD
Trifluoperazine—Asthma—Epirubicin—pancreatic cancer	0.000153	0.00182	CcSEcCtD
Trifluoperazine—Dysphagia—Epirubicin—pancreatic cancer	0.000153	0.00182	CcSEcCtD
Trifluoperazine—Muscle spasms—Docetaxel—pancreatic cancer	0.000152	0.00181	CcSEcCtD
Trifluoperazine—Eosinophilia—Epirubicin—pancreatic cancer	0.000152	0.0018	CcSEcCtD
Trifluoperazine—Dizziness—Sunitinib—pancreatic cancer	0.00015	0.00178	CcSEcCtD
Trifluoperazine—Body temperature increased—Irinotecan—pancreatic cancer	0.000148	0.00176	CcSEcCtD
Trifluoperazine—Pancytopenia—Epirubicin—pancreatic cancer	0.000145	0.00173	CcSEcCtD
Trifluoperazine—Muscular weakness—Doxorubicin—pancreatic cancer	0.000144	0.00172	CcSEcCtD
Trifluoperazine—Body temperature increased—Gemcitabine—pancreatic cancer	0.000144	0.00171	CcSEcCtD
Trifluoperazine—Rash—Sunitinib—pancreatic cancer	0.000143	0.0017	CcSEcCtD
Trifluoperazine—Dermatitis—Sunitinib—pancreatic cancer	0.000143	0.0017	CcSEcCtD
Trifluoperazine—Urticaria—Fluorouracil—pancreatic cancer	0.000142	0.00169	CcSEcCtD
Trifluoperazine—Headache—Sunitinib—pancreatic cancer	0.000142	0.00169	CcSEcCtD
Trifluoperazine—Asthma—Doxorubicin—pancreatic cancer	0.000142	0.00168	CcSEcCtD
Trifluoperazine—Dysphagia—Doxorubicin—pancreatic cancer	0.000142	0.00168	CcSEcCtD
Trifluoperazine—Leukopenia—Docetaxel—pancreatic cancer	0.000142	0.00168	CcSEcCtD
Trifluoperazine—Body temperature increased—Fluorouracil—pancreatic cancer	0.000141	0.00168	CcSEcCtD
Trifluoperazine—ABCB1—digestive system—pancreatic cancer	0.000141	0.00703	CbGeAlD
Trifluoperazine—Eosinophilia—Doxorubicin—pancreatic cancer	0.00014	0.00167	CcSEcCtD
Trifluoperazine—Photosensitivity reaction—Epirubicin—pancreatic cancer	0.00014	0.00166	CcSEcCtD
Trifluoperazine—Weight increased—Epirubicin—pancreatic cancer	0.000139	0.00166	CcSEcCtD
Trifluoperazine—Hyperglycaemia—Epirubicin—pancreatic cancer	0.000138	0.00164	CcSEcCtD
Trifluoperazine—Cough—Docetaxel—pancreatic cancer	0.000138	0.00164	CcSEcCtD
Trifluoperazine—Hypersensitivity—Irinotecan—pancreatic cancer	0.000138	0.00164	CcSEcCtD
Trifluoperazine—Convulsion—Docetaxel—pancreatic cancer	0.000137	0.00163	CcSEcCtD
Trifluoperazine—Drowsiness—Epirubicin—pancreatic cancer	0.000136	0.00162	CcSEcCtD
Trifluoperazine—Nausea—Sunitinib—pancreatic cancer	0.000135	0.0016	CcSEcCtD
Trifluoperazine—Pancytopenia—Doxorubicin—pancreatic cancer	0.000134	0.0016	CcSEcCtD
Trifluoperazine—Asthenia—Irinotecan—pancreatic cancer	0.000134	0.00159	CcSEcCtD
Trifluoperazine—Jaundice—Epirubicin—pancreatic cancer	0.000133	0.00158	CcSEcCtD
Trifluoperazine—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000132	0.00157	CcSEcCtD
Trifluoperazine—Dry mouth—Docetaxel—pancreatic cancer	0.000132	0.00157	CcSEcCtD
Trifluoperazine—Asthenia—Gemcitabine—pancreatic cancer	0.00013	0.00155	CcSEcCtD
Trifluoperazine—Photosensitivity reaction—Doxorubicin—pancreatic cancer	0.000129	0.00154	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Docetaxel—pancreatic cancer	0.000129	0.00153	CcSEcCtD
Trifluoperazine—Weight increased—Doxorubicin—pancreatic cancer	0.000129	0.00153	CcSEcCtD
Trifluoperazine—Pruritus—Gemcitabine—pancreatic cancer	0.000129	0.00153	CcSEcCtD
Trifluoperazine—Hyperglycaemia—Doxorubicin—pancreatic cancer	0.000128	0.00152	CcSEcCtD
Trifluoperazine—Agranulocytosis—Epirubicin—pancreatic cancer	0.000127	0.00151	CcSEcCtD
Trifluoperazine—Pruritus—Fluorouracil—pancreatic cancer	0.000126	0.0015	CcSEcCtD
Trifluoperazine—Drowsiness—Doxorubicin—pancreatic cancer	0.000126	0.0015	CcSEcCtD
Trifluoperazine—Skin disorder—Docetaxel—pancreatic cancer	0.000125	0.00149	CcSEcCtD
Trifluoperazine—Dizziness—Irinotecan—pancreatic cancer	0.000123	0.00147	CcSEcCtD
Trifluoperazine—Jaundice—Doxorubicin—pancreatic cancer	0.000123	0.00146	CcSEcCtD
Trifluoperazine—Anorexia—Docetaxel—pancreatic cancer	0.000123	0.00146	CcSEcCtD
Trifluoperazine—Oedema peripheral—Epirubicin—pancreatic cancer	0.000121	0.00144	CcSEcCtD
Trifluoperazine—Hypotension—Docetaxel—pancreatic cancer	0.000121	0.00143	CcSEcCtD
Trifluoperazine—Dizziness—Fluorouracil—pancreatic cancer	0.000118	0.00141	CcSEcCtD
Trifluoperazine—Agranulocytosis—Doxorubicin—pancreatic cancer	0.000118	0.0014	CcSEcCtD
Trifluoperazine—Rash—Irinotecan—pancreatic cancer	0.000118	0.0014	CcSEcCtD
Trifluoperazine—Dermatitis—Irinotecan—pancreatic cancer	0.000118	0.0014	CcSEcCtD
Trifluoperazine—Headache—Irinotecan—pancreatic cancer	0.000117	0.00139	CcSEcCtD
Trifluoperazine—Insomnia—Docetaxel—pancreatic cancer	0.000117	0.00139	CcSEcCtD
Trifluoperazine—Dyspnoea—Docetaxel—pancreatic cancer	0.000115	0.00137	CcSEcCtD
Trifluoperazine—Somnolence—Docetaxel—pancreatic cancer	0.000115	0.00136	CcSEcCtD
Trifluoperazine—Rash—Gemcitabine—pancreatic cancer	0.000115	0.00136	CcSEcCtD
Trifluoperazine—Dermatitis—Gemcitabine—pancreatic cancer	0.000115	0.00136	CcSEcCtD
Trifluoperazine—Headache—Gemcitabine—pancreatic cancer	0.000114	0.00135	CcSEcCtD
Trifluoperazine—Rash—Fluorouracil—pancreatic cancer	0.000113	0.00134	CcSEcCtD
Trifluoperazine—Dermatitis—Fluorouracil—pancreatic cancer	0.000113	0.00134	CcSEcCtD
Trifluoperazine—Decreased appetite—Docetaxel—pancreatic cancer	0.000112	0.00133	CcSEcCtD
Trifluoperazine—Headache—Fluorouracil—pancreatic cancer	0.000112	0.00133	CcSEcCtD
Trifluoperazine—Oedema peripheral—Doxorubicin—pancreatic cancer	0.000112	0.00133	CcSEcCtD
Trifluoperazine—Fatigue—Docetaxel—pancreatic cancer	0.000111	0.00132	CcSEcCtD
Trifluoperazine—Nausea—Irinotecan—pancreatic cancer	0.000111	0.00132	CcSEcCtD
Trifluoperazine—Constipation—Docetaxel—pancreatic cancer	0.00011	0.00131	CcSEcCtD
Trifluoperazine—Nausea—Gemcitabine—pancreatic cancer	0.000108	0.00128	CcSEcCtD
Trifluoperazine—Erythema—Epirubicin—pancreatic cancer	0.000107	0.00127	CcSEcCtD
Trifluoperazine—Nausea—Fluorouracil—pancreatic cancer	0.000106	0.00126	CcSEcCtD
Trifluoperazine—Nervousness—Epirubicin—pancreatic cancer	0.000104	0.00123	CcSEcCtD
Trifluoperazine—Muscle spasms—Epirubicin—pancreatic cancer	0.000103	0.00122	CcSEcCtD
Trifluoperazine—Body temperature increased—Docetaxel—pancreatic cancer	0.000102	0.00121	CcSEcCtD
Trifluoperazine—Vision blurred—Epirubicin—pancreatic cancer	0.0001	0.0012	CcSEcCtD
Trifluoperazine—Erythema—Doxorubicin—pancreatic cancer	9.87e-05	0.00117	CcSEcCtD
Trifluoperazine—Agitation—Epirubicin—pancreatic cancer	9.8e-05	0.00117	CcSEcCtD
Trifluoperazine—Nervousness—Doxorubicin—pancreatic cancer	9.58e-05	0.00114	CcSEcCtD
Trifluoperazine—Leukopenia—Epirubicin—pancreatic cancer	9.54e-05	0.00114	CcSEcCtD
Trifluoperazine—Hypersensitivity—Docetaxel—pancreatic cancer	9.51e-05	0.00113	CcSEcCtD
Trifluoperazine—Muscle spasms—Doxorubicin—pancreatic cancer	9.49e-05	0.00113	CcSEcCtD
Trifluoperazine—Cough—Epirubicin—pancreatic cancer	9.3e-05	0.00111	CcSEcCtD
Trifluoperazine—Vision blurred—Doxorubicin—pancreatic cancer	9.3e-05	0.00111	CcSEcCtD
Trifluoperazine—Asthenia—Docetaxel—pancreatic cancer	9.26e-05	0.0011	CcSEcCtD
Trifluoperazine—Convulsion—Epirubicin—pancreatic cancer	9.24e-05	0.0011	CcSEcCtD
Trifluoperazine—Pruritus—Docetaxel—pancreatic cancer	9.13e-05	0.00109	CcSEcCtD
Trifluoperazine—Agitation—Doxorubicin—pancreatic cancer	9.07e-05	0.00108	CcSEcCtD
Trifluoperazine—Dry mouth—Epirubicin—pancreatic cancer	8.88e-05	0.00106	CcSEcCtD
Trifluoperazine—Leukopenia—Doxorubicin—pancreatic cancer	8.83e-05	0.00105	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Epirubicin—pancreatic cancer	8.7e-05	0.00104	CcSEcCtD
Trifluoperazine—Cough—Doxorubicin—pancreatic cancer	8.61e-05	0.00102	CcSEcCtD
Trifluoperazine—Convulsion—Doxorubicin—pancreatic cancer	8.55e-05	0.00102	CcSEcCtD
Trifluoperazine—Dizziness—Docetaxel—pancreatic cancer	8.53e-05	0.00101	CcSEcCtD
Trifluoperazine—Skin disorder—Epirubicin—pancreatic cancer	8.45e-05	0.00101	CcSEcCtD
Trifluoperazine—Anorexia—Epirubicin—pancreatic cancer	8.3e-05	0.000987	CcSEcCtD
Trifluoperazine—Dry mouth—Doxorubicin—pancreatic cancer	8.21e-05	0.000977	CcSEcCtD
Trifluoperazine—Rash—Docetaxel—pancreatic cancer	8.14e-05	0.000968	CcSEcCtD
Trifluoperazine—Hypotension—Epirubicin—pancreatic cancer	8.13e-05	0.000967	CcSEcCtD
Trifluoperazine—Dermatitis—Docetaxel—pancreatic cancer	8.13e-05	0.000967	CcSEcCtD
Trifluoperazine—Headache—Docetaxel—pancreatic cancer	8.08e-05	0.000962	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Doxorubicin—pancreatic cancer	8.05e-05	0.000958	CcSEcCtD
Trifluoperazine—Insomnia—Epirubicin—pancreatic cancer	7.87e-05	0.000936	CcSEcCtD
Trifluoperazine—Skin disorder—Doxorubicin—pancreatic cancer	7.82e-05	0.00093	CcSEcCtD
Trifluoperazine—Dyspnoea—Epirubicin—pancreatic cancer	7.76e-05	0.000923	CcSEcCtD
Trifluoperazine—Somnolence—Epirubicin—pancreatic cancer	7.74e-05	0.00092	CcSEcCtD
Trifluoperazine—Anorexia—Doxorubicin—pancreatic cancer	7.68e-05	0.000913	CcSEcCtD
Trifluoperazine—Nausea—Docetaxel—pancreatic cancer	7.66e-05	0.000912	CcSEcCtD
Trifluoperazine—Decreased appetite—Epirubicin—pancreatic cancer	7.57e-05	0.0009	CcSEcCtD
Trifluoperazine—Hypotension—Doxorubicin—pancreatic cancer	7.52e-05	0.000895	CcSEcCtD
Trifluoperazine—Fatigue—Epirubicin—pancreatic cancer	7.5e-05	0.000893	CcSEcCtD
Trifluoperazine—Constipation—Epirubicin—pancreatic cancer	7.44e-05	0.000885	CcSEcCtD
Trifluoperazine—Insomnia—Doxorubicin—pancreatic cancer	7.28e-05	0.000866	CcSEcCtD
Trifluoperazine—Dyspnoea—Doxorubicin—pancreatic cancer	7.18e-05	0.000854	CcSEcCtD
Trifluoperazine—Somnolence—Doxorubicin—pancreatic cancer	7.16e-05	0.000852	CcSEcCtD
Trifluoperazine—Decreased appetite—Doxorubicin—pancreatic cancer	7e-05	0.000833	CcSEcCtD
Trifluoperazine—Fatigue—Doxorubicin—pancreatic cancer	6.94e-05	0.000826	CcSEcCtD
Trifluoperazine—Urticaria—Epirubicin—pancreatic cancer	6.91e-05	0.000822	CcSEcCtD
Trifluoperazine—Constipation—Doxorubicin—pancreatic cancer	6.89e-05	0.000819	CcSEcCtD
Trifluoperazine—Body temperature increased—Epirubicin—pancreatic cancer	6.88e-05	0.000818	CcSEcCtD
Trifluoperazine—Hypersensitivity—Epirubicin—pancreatic cancer	6.41e-05	0.000763	CcSEcCtD
Trifluoperazine—Urticaria—Doxorubicin—pancreatic cancer	6.4e-05	0.000761	CcSEcCtD
Trifluoperazine—Body temperature increased—Doxorubicin—pancreatic cancer	6.37e-05	0.000757	CcSEcCtD
Trifluoperazine—Asthenia—Epirubicin—pancreatic cancer	6.24e-05	0.000743	CcSEcCtD
Trifluoperazine—Pruritus—Epirubicin—pancreatic cancer	6.16e-05	0.000732	CcSEcCtD
Trifluoperazine—Hypersensitivity—Doxorubicin—pancreatic cancer	5.93e-05	0.000706	CcSEcCtD
Trifluoperazine—Asthenia—Doxorubicin—pancreatic cancer	5.78e-05	0.000687	CcSEcCtD
Trifluoperazine—Dizziness—Epirubicin—pancreatic cancer	5.75e-05	0.000685	CcSEcCtD
Trifluoperazine—Pruritus—Doxorubicin—pancreatic cancer	5.7e-05	0.000678	CcSEcCtD
Trifluoperazine—Rash—Epirubicin—pancreatic cancer	5.49e-05	0.000653	CcSEcCtD
Trifluoperazine—Dermatitis—Epirubicin—pancreatic cancer	5.48e-05	0.000652	CcSEcCtD
Trifluoperazine—Headache—Epirubicin—pancreatic cancer	5.45e-05	0.000649	CcSEcCtD
Trifluoperazine—Dizziness—Doxorubicin—pancreatic cancer	5.32e-05	0.000633	CcSEcCtD
Trifluoperazine—Nausea—Epirubicin—pancreatic cancer	5.17e-05	0.000615	CcSEcCtD
Trifluoperazine—Rash—Doxorubicin—pancreatic cancer	5.08e-05	0.000604	CcSEcCtD
Trifluoperazine—Dermatitis—Doxorubicin—pancreatic cancer	5.07e-05	0.000603	CcSEcCtD
Trifluoperazine—Headache—Doxorubicin—pancreatic cancer	5.04e-05	0.0006	CcSEcCtD
Trifluoperazine—Nausea—Doxorubicin—pancreatic cancer	4.78e-05	0.000569	CcSEcCtD
Trifluoperazine—CALM1—Disease—SRC—pancreatic cancer	3.15e-06	3.49e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—CASP3—pancreatic cancer	3.15e-06	3.48e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—STAT3—pancreatic cancer	3.14e-06	3.48e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—NRAS—pancreatic cancer	3.13e-06	3.47e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—GPCR downstream signaling—AKT1—pancreatic cancer	3.13e-06	3.46e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—CCND1—pancreatic cancer	3.12e-06	3.45e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—GPCR downstream signaling—AKT1—pancreatic cancer	3.12e-06	3.45e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—VEGFA—pancreatic cancer	3.1e-06	3.43e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—CASP3—pancreatic cancer	3.1e-06	3.43e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—KRAS—pancreatic cancer	3.09e-06	3.42e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—KRAS—pancreatic cancer	3.09e-06	3.42e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—EGFR—pancreatic cancer	3.09e-06	3.42e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—CTNNB1—pancreatic cancer	3.09e-06	3.42e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—CASP3—pancreatic cancer	3.09e-06	3.42e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—VEGFA—pancreatic cancer	3.08e-06	3.41e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—CCND1—pancreatic cancer	3.07e-06	3.4e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—STAT3—pancreatic cancer	3.07e-06	3.39e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—CCND1—pancreatic cancer	3.06e-06	3.39e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—NRAS—pancreatic cancer	3.06e-06	3.39e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—STAT3—pancreatic cancer	3.05e-06	3.38e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—NRAS—pancreatic cancer	3.05e-06	3.37e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—CTNNB1—pancreatic cancer	3.04e-06	3.36e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—STAT3—pancreatic cancer	3.04e-06	3.36e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—STAT3—pancreatic cancer	3.04e-06	3.36e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—CTNNB1—pancreatic cancer	3.03e-06	3.36e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—NRAS—pancreatic cancer	3.03e-06	3.35e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—NRAS—pancreatic cancer	3.03e-06	3.35e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—MMP9—pancreatic cancer	3.03e-06	3.35e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—HRAS—pancreatic cancer	3.03e-06	3.35e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—CCND1—pancreatic cancer	3.02e-06	3.34e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—PTEN—pancreatic cancer	3.01e-06	3.33e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—CCND1—pancreatic cancer	3.01e-06	3.33e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—EGFR—pancreatic cancer	2.99e-06	3.31e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—EGFR—pancreatic cancer	2.99e-06	3.31e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—CTNNB1—pancreatic cancer	2.99e-06	3.3e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—MMP9—pancreatic cancer	2.98e-06	3.3e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—APOE—pancreatic cancer	2.98e-06	3.3e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—CTNNB1—pancreatic cancer	2.98e-06	3.29e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—MMP9—pancreatic cancer	2.98e-06	3.29e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—PTEN—pancreatic cancer	2.96e-06	3.28e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—PIK3CD—pancreatic cancer	2.96e-06	3.28e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—PTEN—pancreatic cancer	2.96e-06	3.27e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Metabolism—PTEN—pancreatic cancer	2.94e-06	3.25e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling by GPCR—AKT1—pancreatic cancer	2.94e-06	3.25e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by GPCR—PIK3CA—pancreatic cancer	2.94e-06	3.25e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—MMP9—pancreatic cancer	2.93e-06	3.24e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—KRAS—pancreatic cancer	2.92e-06	3.23e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—MYC—pancreatic cancer	2.92e-06	3.23e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—MMP9—pancreatic cancer	2.92e-06	3.23e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—TGFB1—pancreatic cancer	2.91e-06	3.22e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—PTEN—pancreatic cancer	2.91e-06	3.22e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—PTEN—pancreatic cancer	2.9e-06	3.21e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling by GPCR—AKT1—pancreatic cancer	2.89e-06	3.2e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling by GPCR—AKT1—pancreatic cancer	2.89e-06	3.19e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—EGFR—pancreatic cancer	2.86e-06	3.16e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—MYC—pancreatic cancer	2.85e-06	3.15e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—PIK3CB—pancreatic cancer	2.85e-06	3.15e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Metabolism—PTEN—pancreatic cancer	2.85e-06	3.15e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Metabolism—PTEN—pancreatic cancer	2.85e-06	3.15e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—TGFB1—pancreatic cancer	2.84e-06	3.15e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—PIK3CA—pancreatic cancer	2.84e-06	3.14e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—PIK3CA—pancreatic cancer	2.84e-06	3.14e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling by GPCR—AKT1—pancreatic cancer	2.84e-06	3.14e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—MYC—pancreatic cancer	2.84e-06	3.14e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling by GPCR—AKT1—pancreatic cancer	2.83e-06	3.13e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—TGFB1—pancreatic cancer	2.83e-06	3.13e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—KRAS—pancreatic cancer	2.83e-06	3.13e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—KRAS—pancreatic cancer	2.83e-06	3.13e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—MYC—pancreatic cancer	2.82e-06	3.12e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—MYC—pancreatic cancer	2.82e-06	3.12e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	2.82e-06	3.12e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—TGFB1—pancreatic cancer	2.82e-06	3.12e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—TGFB1—pancreatic cancer	2.82e-06	3.12e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—SRC—pancreatic cancer	2.79e-06	3.09e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—EGFR—pancreatic cancer	2.79e-06	3.08e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—EGFR—pancreatic cancer	2.77e-06	3.07e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—EGFR—pancreatic cancer	2.76e-06	3.06e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—EGFR—pancreatic cancer	2.76e-06	3.06e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—PIK3CB—pancreatic cancer	2.75e-06	3.05e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—PIK3CB—pancreatic cancer	2.75e-06	3.05e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—SRC—pancreatic cancer	2.75e-06	3.04e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—SRC—pancreatic cancer	2.74e-06	3.03e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—CXCL8—pancreatic cancer	2.74e-06	3.03e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—VEGFA—pancreatic cancer	2.72e-06	3.01e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by GPCR—HRAS—pancreatic cancer	2.72e-06	3.01e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—SRC—pancreatic cancer	2.7e-06	2.99e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—KRAS—pancreatic cancer	2.7e-06	2.98e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—STAT3—pancreatic cancer	2.69e-06	2.98e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—SRC—pancreatic cancer	2.69e-06	2.98e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—PIK3CG—pancreatic cancer	2.69e-06	2.97e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—NRAS—pancreatic cancer	2.69e-06	2.97e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—PIK3CA—pancreatic cancer	2.68e-06	2.97e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—VEGFA—pancreatic cancer	2.68e-06	2.96e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—VEGFA—pancreatic cancer	2.67e-06	2.96e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—AKT1—pancreatic cancer	2.67e-06	2.95e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—STAT3—pancreatic cancer	2.65e-06	2.93e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—CXCL8—pancreatic cancer	2.65e-06	2.93e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—CXCL8—pancreatic cancer	2.65e-06	2.93e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—STAT3—pancreatic cancer	2.65e-06	2.93e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—NRAS—pancreatic cancer	2.64e-06	2.93e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—NRAS—pancreatic cancer	2.64e-06	2.92e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—KRAS—pancreatic cancer	2.63e-06	2.91e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—HRAS—pancreatic cancer	2.63e-06	2.91e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—HRAS—pancreatic cancer	2.63e-06	2.91e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—VEGFA—pancreatic cancer	2.63e-06	2.91e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—VEGFA—pancreatic cancer	2.62e-06	2.9e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—KRAS—pancreatic cancer	2.62e-06	2.9e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—CASP3—pancreatic cancer	2.62e-06	2.9e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—KRAS—pancreatic cancer	2.61e-06	2.89e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—KRAS—pancreatic cancer	2.61e-06	2.89e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—STAT3—pancreatic cancer	2.6e-06	2.88e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—PIK3CA—pancreatic cancer	2.6e-06	2.87e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—PIK3CA—pancreatic cancer	2.6e-06	2.87e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—NRAS—pancreatic cancer	2.6e-06	2.87e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—STAT3—pancreatic cancer	2.6e-06	2.87e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—PPARG—pancreatic cancer	2.6e-06	2.87e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—NRAS—pancreatic cancer	2.59e-06	2.86e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—PIK3CB—pancreatic cancer	2.58e-06	2.85e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—PTGS2—pancreatic cancer	2.56e-06	2.83e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—CCND1—pancreatic cancer	2.55e-06	2.82e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—CASP3—pancreatic cancer	2.53e-06	2.8e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—CASP3—pancreatic cancer	2.53e-06	2.8e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—CTNNB1—pancreatic cancer	2.52e-06	2.79e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—MYC—pancreatic cancer	2.5e-06	2.77e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—TGFB1—pancreatic cancer	2.5e-06	2.76e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—HRAS—pancreatic cancer	2.48e-06	2.75e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—PIK3CA—pancreatic cancer	2.48e-06	2.74e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—MMP9—pancreatic cancer	2.48e-06	2.74e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—CCND1—pancreatic cancer	2.47e-06	2.73e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—CCND1—pancreatic cancer	2.47e-06	2.73e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—MYC—pancreatic cancer	2.46e-06	2.72e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—PTEN—pancreatic cancer	2.46e-06	2.72e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—MYC—pancreatic cancer	2.46e-06	2.72e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—TGFB1—pancreatic cancer	2.46e-06	2.72e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—TGFB1—pancreatic cancer	2.45e-06	2.71e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—EGFR—pancreatic cancer	2.45e-06	2.71e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—CTNNB1—pancreatic cancer	2.44e-06	2.7e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—CTNNB1—pancreatic cancer	2.44e-06	2.7e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—PIK3CA—pancreatic cancer	2.42e-06	2.68e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—MYC—pancreatic cancer	2.42e-06	2.68e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—TGFB1—pancreatic cancer	2.41e-06	2.67e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—MYC—pancreatic cancer	2.41e-06	2.67e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—EGFR—pancreatic cancer	2.41e-06	2.67e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—PIK3CA—pancreatic cancer	2.41e-06	2.66e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—TGFB1—pancreatic cancer	2.41e-06	2.66e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—EGFR—pancreatic cancer	2.4e-06	2.66e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—HRAS—pancreatic cancer	2.4e-06	2.66e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—HRAS—pancreatic cancer	2.4e-06	2.66e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by GPCR—AKT1—pancreatic cancer	2.4e-06	2.66e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—PIK3CA—pancreatic cancer	2.4e-06	2.65e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—PIK3CA—pancreatic cancer	2.4e-06	2.65e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—MMP9—pancreatic cancer	2.39e-06	2.65e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—MMP9—pancreatic cancer	2.39e-06	2.65e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—PTEN—pancreatic cancer	2.38e-06	2.63e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—PTEN—pancreatic cancer	2.38e-06	2.63e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—EGFR—pancreatic cancer	2.37e-06	2.62e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—PIK3CD—pancreatic cancer	2.36e-06	2.61e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—EGFR—pancreatic cancer	2.36e-06	2.61e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—TP53—pancreatic cancer	2.34e-06	2.59e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—TP53—pancreatic cancer	2.33e-06	2.58e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—AKT1—pancreatic cancer	2.32e-06	2.57e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—AKT1—pancreatic cancer	2.32e-06	2.57e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—KRAS—pancreatic cancer	2.31e-06	2.56e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—HRAS—pancreatic cancer	2.29e-06	2.54e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—SRC—pancreatic cancer	2.28e-06	2.52e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—KRAS—pancreatic cancer	2.28e-06	2.52e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—KRAS—pancreatic cancer	2.27e-06	2.51e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—HRAS—pancreatic cancer	2.24e-06	2.48e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—KRAS—pancreatic cancer	2.23e-06	2.47e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—PTEN—pancreatic cancer	2.23e-06	2.47e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—KRAS—pancreatic cancer	2.23e-06	2.47e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—HRAS—pancreatic cancer	2.23e-06	2.46e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—VEGFA—pancreatic cancer	2.22e-06	2.46e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—HRAS—pancreatic cancer	2.22e-06	2.45e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—HRAS—pancreatic cancer	2.22e-06	2.45e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—SRC—pancreatic cancer	2.21e-06	2.44e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—SRC—pancreatic cancer	2.21e-06	2.44e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—STAT3—pancreatic cancer	2.2e-06	2.43e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—NRAS—pancreatic cancer	2.2e-06	2.43e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—AKT1—pancreatic cancer	2.19e-06	2.43e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—VEGFA—pancreatic cancer	2.15e-06	2.38e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—VEGFA—pancreatic cancer	2.15e-06	2.38e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—STAT3—pancreatic cancer	2.13e-06	2.35e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—STAT3—pancreatic cancer	2.13e-06	2.35e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—PIK3CA—pancreatic cancer	2.13e-06	2.35e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—NRAS—pancreatic cancer	2.12e-06	2.35e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—NRAS—pancreatic cancer	2.12e-06	2.35e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—AKT1—pancreatic cancer	2.12e-06	2.35e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—AKT1—pancreatic cancer	2.12e-06	2.35e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—PIK3CA—pancreatic cancer	2.09e-06	2.31e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—PIK3CA—pancreatic cancer	2.09e-06	2.31e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Metabolism—PIK3CA—pancreatic cancer	2.08e-06	2.3e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—PIK3CB—pancreatic cancer	2.06e-06	2.28e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—TP53—pancreatic cancer	2.06e-06	2.27e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—PIK3CA—pancreatic cancer	2.05e-06	2.27e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—PIK3CA—pancreatic cancer	2.05e-06	2.26e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—MYC—pancreatic cancer	2.04e-06	2.26e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—PTGS2—pancreatic cancer	2.04e-06	2.26e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—TGFB1—pancreatic cancer	2.04e-06	2.26e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—AKT1—pancreatic cancer	2.03e-06	2.24e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—TP53—pancreatic cancer	2.02e-06	2.24e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—TP53—pancreatic cancer	2.02e-06	2.23e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Metabolism—PIK3CA—pancreatic cancer	2.01e-06	2.22e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Metabolism—PIK3CA—pancreatic cancer	2.01e-06	2.22e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—EGFR—pancreatic cancer	2e-06	2.21e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—TP53—pancreatic cancer	1.99e-06	2.2e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—TP53—pancreatic cancer	1.98e-06	2.19e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—MYC—pancreatic cancer	1.98e-06	2.19e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—MYC—pancreatic cancer	1.98e-06	2.19e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—AKT1—pancreatic cancer	1.98e-06	2.19e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—TGFB1—pancreatic cancer	1.97e-06	2.18e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—TGFB1—pancreatic cancer	1.97e-06	2.18e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—AKT1—pancreatic cancer	1.97e-06	2.18e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—HRAS—pancreatic cancer	1.97e-06	2.17e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—AKT1—pancreatic cancer	1.96e-06	2.17e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—AKT1—pancreatic cancer	1.96e-06	2.17e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—EGFR—pancreatic cancer	1.93e-06	2.14e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—EGFR—pancreatic cancer	1.93e-06	2.14e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—HRAS—pancreatic cancer	1.93e-06	2.14e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—HRAS—pancreatic cancer	1.93e-06	2.14e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—HRAS—pancreatic cancer	1.9e-06	2.1e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—HRAS—pancreatic cancer	1.89e-06	2.1e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—KRAS—pancreatic cancer	1.89e-06	2.09e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—KRAS—pancreatic cancer	1.83e-06	2.02e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—KRAS—pancreatic cancer	1.83e-06	2.02e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—PTEN—pancreatic cancer	1.78e-06	1.97e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—AKT1—pancreatic cancer	1.74e-06	1.92e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—PIK3CA—pancreatic cancer	1.74e-06	1.92e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—AKT1—pancreatic cancer	1.71e-06	1.89e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—AKT1—pancreatic cancer	1.7e-06	1.89e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Metabolism—AKT1—pancreatic cancer	1.7e-06	1.88e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—TP53—pancreatic cancer	1.68e-06	1.86e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—PIK3CA—pancreatic cancer	1.68e-06	1.86e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—PIK3CA—pancreatic cancer	1.68e-06	1.86e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—AKT1—pancreatic cancer	1.68e-06	1.86e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—AKT1—pancreatic cancer	1.67e-06	1.85e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Metabolism—AKT1—pancreatic cancer	1.64e-06	1.81e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Metabolism—AKT1—pancreatic cancer	1.64e-06	1.81e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—TP53—pancreatic cancer	1.62e-06	1.8e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—TP53—pancreatic cancer	1.62e-06	1.8e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—HRAS—pancreatic cancer	1.61e-06	1.78e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—PIK3CA—pancreatic cancer	1.57e-06	1.74e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—HRAS—pancreatic cancer	1.55e-06	1.72e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—HRAS—pancreatic cancer	1.55e-06	1.72e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—AKT1—pancreatic cancer	1.42e-06	1.57e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—AKT1—pancreatic cancer	1.37e-06	1.52e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—AKT1—pancreatic cancer	1.37e-06	1.52e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—AKT1—pancreatic cancer	1.29e-06	1.42e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—PIK3CA—pancreatic cancer	1.26e-06	1.39e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—AKT1—pancreatic cancer	1.03e-06	1.13e-05	CbGpPWpGaD
